Clear intelligence on complicated diseases.

Coverage of cancer treatment, diagnosis, and access. Where the science is moving, where the access bottlenecks are, and what is changing in the patient pathway.

Coverage of rare disease drug development, diagnostic odysseys, gene therapy delivery, and the access pathways for treatments that serve small patient populations.

Coverage of immune-mediated disease - autoimmunity, biologics, biosimilars, and the comorbidity patterns that shape how immunology drugs are actually used.

Coverage of neurology - Alzheimer's, Parkinson's, multiple sclerosis, and the broader neurodegenerative pipeline, plus the diagnostic and delivery infrastructure these therapies depend on at scale.

Coverage of cardiometabolic disease - the GLP-1 reshaping of obesity and diabetes, cardiovascular outcomes, and the prevention-versus-treatment frame.

Coverage of respiratory disease - severe asthma biologics, COPD, inhalation delivery, and the populations the trials still leave behind.

Coverage of women's health - contraception, menopause, fertility, and maternal health. The areas where the evidence base and the regulatory attention have lagged the population need.

Coverage of mental health - the psychedelic clinical pipeline, digital therapeutics, the difficult-to-treat populations, and the system that has to deliver any of it.

Coverage of ophthalmology - retinal disease, glaucoma, dry eye, and the imaging and intravitreal-injection infrastructure that gates access to approved therapy.